Mining company Fortescue, which alleges green iron startup Element Zero misused confidential information, is fighting a bid to cross-examine its external lawyer as part of an application to quash search orders.
Seeking to quash search orders won by metals company Fortescue against former employees who founded a green iron rival, a lawyer for the start-up has said three terabytes of data were indiscriminately copied, including confidential, privileged and irrelevant material.
Metal mining company Fortescue hired private investigators to spy on former employees who created green iron start-up Element Zero, sifting through their mail, taking photos of their children and following them to Kmart, a court has heard.
Start-up Element Zero claims Fortescue did not disclose material information to the court when it obtained search orders in its case alleging “industrial scale misuse” of the mining company’s confidential information.
A three-year court battle over PepsiCo’s Monster Munch trade mark has been resolved, with Monster Energy negotiating the removal of some beverage products that would have been covered by the mark.C
Fortescue has brought legal action against start-up Element Zero and three former employees, alleging “industrial scale misuse” of the Western Australian mining company’s confidential information.
IP services giant IPH Limited, which owns IP boutiques Spruson & Ferguson and Griffith Hack, has made an offer worth $265 million to acquire its rival QANTM Limited, after failing to woo its main competitor with a takeover bid in 2018.
KFC has failed to block Grill’d’s HFC trade mark, with a judge finding the marks are not deceptively similar and that Grill’d did not act in bad faith despite parodying the fast food giant in advertising for its ‘Healthy Fried Chicken’ products.
Novartis unit Sandoz AG has filed an appeal after it was was barred from selling a generic version of top-selling blood clot drug Xarelto and failed to revoke two Bayer patents for the drug.
Novartis unit Sandoz AG has lost its bid to revoke Bayer’s patents for its top-selling blood clot drug Xarelto and has been barred from selling generic versions of the medication after a judge found the German pharma giant’s patents were valid.